Synopsis: Morgan Stanley maintains an overweight rating on PI Industries, citing 40 percent upside. Weak agchem exports are offset by strong CDMO performance, favorable margins, and new product launches, supporting long-term growth potential.
The article outlines PI Industries’ current performance and market outlook, highlighting Morgan Stanley’s overweight rating with 39.6percent upside. It examines near-term agchem export weakness, strong CDMO and Pharma 1 growth, margin trends, and strategic product launches supporting long-term value creation.
With a market capitalization of Rs 42,214 crore, P I Industries Ltd’s shares closed at Rs 2,782.40 per share, up by 0.81percent from its previous day’s close price. The share of this company has given a return of 22 percent over the last five years.
Brokerage View
Morgan Stanley continues to rate PI Industries as overweight, seeing 39.6 percent upside with a target price of Rs 3,883. While agchem faces short-term weakness, strong long-term growth and a high-margin CDMO business make the stock attractive.
Rationale
Agchem Export Weakness: Weakness in agricultural chemical exports is weighing on the company’s near-term performance, with slower order inflows and subdued utilisation levels limiting growth visibility. Key export markets remain soft, contributing to a cautious outlook for the upcoming fiscal periods.
Financial Projections & Cuts: Morgan Stanley has revised down its forecasts, cutting EBITDA by 11 to 12 percent for FY26–FY28. The adjustments reflect margin pressure from lower operating leverage, pricing challenges, and delayed recovery in export volumes, impacting both profitability and EPS expectations.
Business highlights
Margin and Profit Dynamics: Gross margins improved due to a favorable product mix and cost discipline. Overheads rose 6 percent from strategic business development and new product promotions, partially offset by savings in existing operations. Net profit includes Rs 1260 Mn exceptional income from contingent consideration writeback, partly offset by Rs 209 Mn additional retirement benefit provisions under the new labor code.
Agchem & Domestic Crop Solutions Performance: Agchem exports fell 20 percent YoY (volume down ~16 percent) due to a high base effect, partly offset by 10 percent growth in new products. Five new molecules were commercialized in 9MFY26, including differentiated Flow and Vapor Phase technologies. Domestic revenue declined ~6 percent YoY due to higher channel inventories, adverse weather, and lower crop prices.
Pharma 1 Growth(CDMO Strength) and Operational Efficiency: Pharma 1 revenue grew 50 percent YoY, contributing ~5 percent of total export revenue, supported by onboarding new customers and expanding the opportunity funnel. Regulatory approvals for Harpin αβ in India and a biochemical pesticide in the US enhanced market potential. EBITDA margin remained healthy at 27 percent, driven by a favorable product mix and strong operational efficiency.
PI Industries Ltd is a leading player in the agro-chemicals space, having a strong presence in both Domestic and Export markets. It has state-of-the-art facilities in Gujarat having integrated process development teams and in-house engineering capabilities.
Financial Highlights: The revenue from operations declined by 28 percent to Rs 1,376 crore in Q3 FY26 from Rs 1,901 crore in Q3 FY25, and EBIDT declined by 41 percent to Rs 302 crore in Q3 FY26 from Rs 512 crore in Q3 FY25. Accompanied by a net profit decline of 40 percent to Rs 311 crore in Q3 FY26 from Rs 373 crore in Q3 FY25, resulting in an EPS decline of 16 percent to Rs 20.52 per share in Q3 FY26.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
